Variables | Univariate model | Multivariate model | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p-value | HR | 95% CI | p-value | |
Gender | ||||||
Male | Ref | |||||
Female | 1.09 | (0.75–1.58) | 0.65 | |||
Agea, year | 1.07 | (1.04–1.09) | < 0.001 | 1.09 | (1.05–1.13) | < 0.001 |
BMIa, kg/m2 | ||||||
< 25 | Ref | Ref | ||||
≥ 25 | 1.68 | (0.89–3.16) | 0.11 | 1.42 | (0.73–2.76) | 0.30 |
Route of transmission | 0.008 | 0.19 | ||||
Heterosexual | Ref | Ref | ||||
MSM/bisexual | 0.54 | (0.35–0.82) | 0.004 | 1.74 | (0.95–3.21) | 0.07 |
IDU/others/unknown | 0.66 | (0.33–1.30) | 0.23 | 1.06 | (0.32–3.53) | 0.93 |
Ever smoking | 0.82 | (0.56–1.20) | 0.31 | |||
Ever alcohol drinking | 0.82 | (0.38–1.77) | 0.62 | |||
Baseline HIV-RNA level (log10 copies/mL) | 1.19 | (0.92–1.54) | 0.19 | |||
Baseline CDC grading | ||||||
Stage A or B | Ref | |||||
Stage C | 1.03 | (0.61–1.74) | 0.92 | |||
Tuberculosis infectiona | ||||||
No | Ref | |||||
Yes | 1.24 | (0.17–8.93) | 0.83 | |||
Time since ART initiation to first viral suppression | 0.057 | |||||
< 6 months | Ref | |||||
6–12 months | 0.48 | (0.22–1.06) | 0.07 | |||
≥ 12 months | 1.14 | (0.79–1.64) | 0.49 | |||
Current CD4 counts per 100 increased | 0.93 | (0.85–1.02) | 0.12 | |||
Current CD4/CD8 | ||||||
< 0.3 | 3.10 | (1.87–5.14) | < 0.001 | 3.02 | (1.27–7.21) | 0.001 |
0.30–0.45 | 1.76 | (1.13–2.75) | 0.01 | 2.03 | (1.03–3.98) | 0.04 |
> 0.45 | Ref | Ref | ||||
Diabetes mellitus | 2.27 | (1.52–3.39) | < 0.001 | 3.02 | (0.06–163.26) | 0.59 |
HBs Ag status | ||||||
Negative | Ref | |||||
Positive | 0.69 | (0.40–1.18) | 0.17 | |||
Anti-HCV Ab status | ||||||
Negative | Ref | |||||
Positive | 1.04 | (0.54–1.98) | 0.92 | |||
Baseline ARV regimen | ||||||
NNRTI-based | Ref | Ref | ||||
PI-based | 1.55 | (1.09–2.22) | 0.015 | 1.09 | (0.6–1.99) | 0.77 |
cART by calendar year | ||||||
< 2007 | Ref | Ref | ||||
≥ 2007 | 0.40 | (0.27–0.61) | < 0.001 | 1.29 | (0.7–2.36) | 0.42 |